Diagnostic Performance of 99mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism
Experimental and Clinical Endocrinology & Diabetes · 01.04.2024 · 132 (04) · 216-220
DOI: 10.1055/a-2262-9249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.04.2024. Verfasst von Ante Mandic und 7 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: Parathyroid Glands, Hyperparathyroidism, Primary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aimed to assess the diagnostic performance of 99mTc-sestamibi SPECT/CT and 18F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT).
Methods
A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either 99mTc-sestamibi SPECT/CT (81 patients) or 18F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients, 18F-choline PET/CT was performed after negative or inconclusive findings on 99mTc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings.
Results
The study encompassed 83 patients (70 females, 84.3%) with an average age of 57.2 years (24–80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of 99mTc-sestamibi SPECT/CT was 57% (95% CI 45.3–68.1), while the detection rate of 18F-choline PET/CT was 90.3% (95% CI 74.3–98.0).
Conclusion
The results of our study showed the significant usefulness of 18F-choline PET/CT in patients with negative or inconclusive results of 99mTc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
- School of Medicine, University of Zagreb, Croatia.
ORCID-Profile: Ante Mandic
Zitieren
APA
Mandic, A., Kraljevic, I., Skoric Polovina, T., Zibar Tomsic, K., Dusek, T., Balasko, A., Solak, M., & Kastelan, D. (2024). Diagnostic Performance of 99mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism. Experimental and Clinical Endocrinology & Diabetes, 132(04), 216-220. https://doi.org/10.1055/a-2262-9249
Vancouver
Mandic A, Kraljevic I, Skoric Polovina T, Zibar Tomsic K, Dusek T, Balasko A, et al. Diagnostic Performance of 99mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism. Experimental and Clinical Endocrinology & Diabetes. 2024;132(04):216-220. doi:10.1055/a-2262-9249
BibTeX
@article{Mandic2024,
author = {Mandic, Ante and Kraljevic, Ivana and Skoric Polovina, Tanja and Zibar Tomsic, Karin and Dusek, Tina and Balasko, Annemarie and Solak, Mirsala and Kastelan, Darko},
title = {Diagnostic Performance of 99mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2024},
volume = {132},
number = {04},
pages = {216--220},
doi = {10.1055/a-2262-9249}
}
EUVIMED